Department of Clinical Pharmacology, Flinders University, Adelaide, Australia.
Curr Vasc Pharmacol. 2011 May;9(3):358-80. doi: 10.2174/157016111795495503.
Vascular endothelial growth factor (VEGF) is an endogenous polypeptide that modulates angiogenesis in normal physiological conditions as well as in cancer. During angiogenesis, VEGF interacts with several other angiogenic factors, playing an important role in cell proliferation, differentiation, migration, cell survival, nitric oxide (NO) production, release of other growth factors and sympathetic innervation. Based on these mechanisms of action, several anti-VEGF drugs have been developed for cancer treatment. This review discusses the physiology and interactions of VEGF, its mechanisms of action and role in modulating vascular homeostasis. It also discusses the adverse cardiovascular effects of recently developed anti-VEGF drugs for the treatment of various types of cancer. A critical appraisal of the human studies on these drugs is provided. Furthermore, putative mechanisms for the onset of hypertension, the most common adverse cardiovascular effect, are discussed.
血管内皮生长因子(VEGF)是一种内源性多肽,在正常生理条件和癌症中调节血管生成。在血管生成过程中,VEGF 与其他几种血管生成因子相互作用,在细胞增殖、分化、迁移、细胞存活、一氧化氮(NO)产生、其他生长因子的释放和交感神经支配中发挥重要作用。基于这些作用机制,已经开发了几种抗 VEGF 药物用于癌症治疗。本文讨论了 VEGF 的生理学和相互作用、作用机制及其在调节血管稳态中的作用。还讨论了最近开发的用于治疗各种类型癌症的抗 VEGF 药物的不良心血管作用。对这些药物的人体研究进行了批判性评估。此外,还讨论了高血压(最常见的不良心血管作用)发生的潜在机制。